View this email online 

Audax and Greenbriar line up sale for logistics provider; pharma services attract more PE interest, says Raymond James

Good morning, Hubsters. Senior reporter Michael Schoeck here with the US edition of the Wire from the New York newsroom.

Today we’ll have a look at myfirst ‘On the block’ series article of the year, focused on freight, transportation and logistics companies for sale.

Next we’ll have the latest rundown of companies for sale from what sources have told PE Hub.

And we’ll round up with insight from Raymond James on increased private equity interest in pharmaceutical services.

Shipping an exit strategy

PE Hub reporters are actively reaching out to sources on PE-backed companies – and companies owned by strategics likely to attract private equity interest – that are expected to go up for sale.

We’ll publish reports on individual companies that sources say are coming to market or have initiated a sale process in recent weeks. And we’ll update you with round-ups like this one, which focuses on transportation, freight and logistics companies.

Sign up for the premium version of the Wire to read about freight and logistics companies for sale.

On the block

Despite the slow start for M&A this year, sale processes are starting to pick up.

So far in 2025, confidential sources have alerted me to dozens of companies and corporate carveouts that are expected to test the market in the coming months.

Upgrade to the premium version of the Wire for more intel on companies for sale.

If you’ve got tips on companies coming to the market, shoot me a note at [email protected].

Injectable dealflow

Healthcare-focused private equity firms seeking to bolster company platforms in drug research, development and commercialization have become a larger buyer group of the pharmaceutical services market.

In a Q1 2025 update titled ‘Pharma Services Insights,’ investment bank Raymond James noted that a majority of pharma services market deals in 2024 involved a private equity platform or PE add-on deal.

Sign up for the premium version of the Wire for more pharma services insight.

That’s a wrap for me.  Keep an eye out for the Europe edition of the Wire tomorrow from Irien Joseph and the US edition from John R Fischer.

Cheers,

Michael

Read the full Wire commentary on PE Hub ...

Also of note (may require subscriptions)

AnaCap has six bolt-on targets in the “advanced” pipeline for its insurance brokerage platform Edge Group, as it aims to expand the business in Italy, managing director Alberto Sainaghi told PE Hub.

Oaktree Capital Management has announced a final close for its Oaktree Opportunities Fund XII with roughly $16 billion in commitments, including co-investments and affiliated investment vehicles. (Private Debt Investor)

Certain investing tailwinds are rising with the election of Donald Trump as US president, with digital infrastructure and the realignment of supply chains being two areas of potential opportunity under the new administration. That’s according to Stonepeak chief executive Michael Dorrell, who spoke in front of the Washington State Investment Board on 6 February. (Infrastructure Investor)

Private Equity International is out with its latest Placement Agent Ranking, which lists the most active external fundraising firms by new capital raised for clients in the 12 months to end-May.

Are digital infra and the energy transition too much of a good thing? Investors want exposure to the mega-trends, but they may not like the concentration risk that comes with it. (Infrastructure Investor)

Credit continued its run as one of the most important parts of Brookfield Asset Management’s entire platform, maintaining its role as the single-largest source of assets and fee-bearing capital, according to its 2024 year-end and fourth-quarter earnings report. (Private Debt Investor)

Deals

They said it

“Broadly speaking we expect more pharma services assets to test the market this year as a natural function of the backlog of assets currently owned by private equity.”

— Don Matz, a managing director at Raymond James, on the firm’s 2025 deal outlook.

Today's letter was prepared by Michael Schoeck

Did someone forward you this email? Subscribe now to get full, unlimited access to all PE Hub content, including every PE Hub Wire article.

Please visit Buyouts for the latest insight into LP activity and Venture Capital Journal for comprehensive coverage and analysis of what’s happening in VC. 

London | New York | Hong Kong | Tokyo | Sydney

PEI Group Ltd is registered in England no.6135779

Registered office: 5th Floor, 100 Wood Street, EC2V 7AN

To update your PE Hub email preferences, or to unsubscribe, click here.